Form 4: uniQure Director David Meek Receives Significant Equity Grants

uniQure N.V. Director David D. Meek has reported the acquisition of 7,970 restricted share units and 15,630 stock options, granted as part of the company's 2014 Share Incentive Plan.

Summary

• David D. Meek, a Director of uniQure N.V. (QURE), reported changes in his beneficial ownership of company securities on June 11, 2025.
• He acquired 7,970 Ordinary Shares in the form of Restricted Share Units (RSUs) at a price of $0. These RSUs represent the contingent right to receive one Ordinary Share each.
• The RSUs are set to vest 100% on the first anniversary of the grant date, which is June 11, 2026, contingent upon Mr. Meek's continued relationship with uniQure.
• Following this transaction, Mr. Meek directly beneficially owns 36,302 Ordinary Shares.
• Additionally, Mr. Meek acquired 15,630 Stock Options (right to buy) at an exercise price of $16.22 per share, also granted at a price of $0.
• These Stock Options will also vest 100% on the first anniversary of the grant date, June 11, 2026, subject to his continued relationship with the Issuer.
• The Stock Options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Meek directly beneficially owns 15,630 Stock Options.

Sentiment

Score: 7

Explanation: The document reports routine equity grants to a director, which is a positive for aligning management incentives with shareholder interests. It does not contain negative financial news or operational setbacks, nor does it indicate extraordinary positive events beyond standard compensation.

Positives

• The grant of restricted share units and stock options aligns the director's financial interests directly with the long-term performance and shareholder value of uniQure N.V.
• Equity compensation serves as a strong incentive for continued service and dedication from key management and directors.
• The grants are part of an established incentive plan (2014 Share Incentive Plan), indicating a structured approach to executive compensation.

Risks

• The vesting of both the restricted share units and stock options is contingent upon the reporting person's continued relationship with uniQure N.V. through the vesting date. If the relationship ceases before June 11, 2026, the unvested equity may be forfeited.
• The value of the stock options is dependent on the future market price of uniQure's Ordinary Shares exceeding the exercise price of $16.22.

Future Outlook

The equity grants provide a forward-looking incentive for Director David D. Meek, aligning his future compensation with the company's performance and shareholder returns through the vesting period and the life of the options.

Industry Context

The granting of restricted share units and stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to attract, retain, and incentivize key personnel. This practice aims to align the interests of directors with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of equity-based compensation, specifically restricted share units and stock options, is a standard practice for director remuneration in the biotech sector, comparable to compensation structures seen at companies like BioNTech, Moderna, or Regeneron Pharmaceuticals, which also utilize equity to incentivize long-term commitment and performance.
• The vesting schedule of 100% on the first anniversary of the grant date is a common approach for director grants, designed to ensure continued engagement over at least a one-year period.
• The specific number of units and options granted would typically be benchmarked against peer group companies of similar market capitalization and stage of development, though this document does not provide the necessary data for a direct quantitative comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants are intended to align the director's interests with shareholders by incentivizing long-term stock performance.
• Employees: While not directly impacting all employees, such compensation practices for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted share units and stock options are scheduled to vest on June 11, 2026, subject to the director's continued relationship with uniQure N.V.

Key Dates

Keywords

uniQure, QURE, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Share Units, Stock Options, Equity Compensation, Director Compensation, Incentive Plan